Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

← catalyst calendar

NCT07001800 · readout in 742 d

Sponsored by Kardigan, Inc. (industry) · KARD — their whole pipeline →.

Phase

Phase 2/3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

1,276estimated

Sites

Countries

Canada, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-06-27

actual

When the study began enrolling

Primary completion

2028-08-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-09-30

estimated

The whole study's end, after follow-up

First posted

2025-06-03

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-06

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Moderate Aortic Valve Stenosis

Interventions

Drug: Ataciguat
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

(Part A) Change in Aortic Valve Calcium (AVC) score as assessed by non-contrast CT from baseline to Week 24

measured Week 24

(Part B Dual-Primary) Percent change in Aortic Valve Area (AVA) as measured by echocardiogram from baseline to Week 48

measured Week 48

(Part B Dual-Primary) Change in peak VO2 by CPET from baseline to Week 48

measured Week 48

Publications

PMID 42592935 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · KARD's whole pipeline · Catalyst calendar · Every registered study · What changed